Jan'05 | Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF to Net Income | 67.0% | 155.1% | 108.6% | 85.4% | 46.7% | 41.0% | 48.2% | 84.8% | 71.5% | 88.3% | 89.7% | 85.6% | (46.9%) | 139.2% | (535.1%) | 66.3% | 92.1% | 82.3% | 53.6% | 12.5% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month FCF to Net Income is 57.4%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for Summit Therapeutics Inc. have been 58.4% over the past three years, and 70.8% over the past five years.
As of today, Summit Therapeutics Inc.'s FCF to Net Income is 57.4%, which is lower than industry median of 84.2%. It indicates that Summit Therapeutics Inc.'s FCF to Net Income is Bad.